jcp quiz

Quizzes

Quiz

Quiz: Costs and Health Care Resource Utilization in Patients With Metastatic, Castration-Resistant vs Nonmetastatic Prostate Cancer

05/02/2022

True or False: Compared with patients with nonmetastatic, hormone-sensitive prostate cancer (HSPC), overall annual out-of-pocket costs were higher for patients with metastatic, HSPC.

True or False: Compared with...

05/02/2022

Journal of Clinical Pathways

Quiz

Quiz: First-Line Venetoclax Plus Obinutuzumab Among Patients With CLL or SLL

04/18/2022

True or False: Patients with CLL or SLL who discontinued venetoclax as first-line therapy had a greater disease burden and risk of tumor lysis syndrome when compared with patients who completed at least 12 cycles of treatment with venetoclax.

True or False: Patients with CLL...

04/18/2022

Journal of Clinical Pathways

Quiz

Quiz: Survival Outcomes in Patients With MCL Treated With Bruton Tyrosine Kinase Inhibitors

04/12/2022

True or False: BTK inhibitors in the second-line setting improve overall survival and lymphoma-specific survival among patients with MCL.

True or False: BTK inhibitors in...

04/12/2022

Journal of Clinical Pathways

Sponsored

Quiz by Sanofi

Prevention of High Uric Acid Levels in Patients Receiving Anticancer Therapies

04/11/2022

Test your knowledge with this engaging 5 question quiz exploring the risk of tumor lysis syndrome among patients receiving anticancer therapies.

Test your knowledge with this...

04/11/2022

Journal of Clinical Pathways

Quiz

Quiz: Safety and Efficacy of Belantamab Mafodotin for Relapsed/Refractory MM

04/06/2022

True or False: In the real-world setting, belantamab mafodotin demonstrates comparable responses and toxicities in patients with multiple myeloma to those seen in clinical trials.

True or False: In the real-world...

04/06/2022

Journal of Clinical Pathways

Quiz

Quiz: Cost of Biosimilars vs Biologics in Cancer Care

03/31/2022

True or False: Biosimilars may provide lower-cost alternatives to biologics used in cancer care.

True or False: Biosimilars may...

03/31/2022

Journal of Clinical Pathways

Sponsored

Quiz by Sanofi

Treatment Approaches in Metastatic Castration-Resistant Prostate Cancer

03/29/2022

Test your knowledge with this 5 question quiz exploring the treatment of patients with metastatic castration-resistant prostate cancer.

Test your knowledge with this 5...

03/29/2022

Journal of Clinical Pathways

Quiz

Quiz: The Impact of Atrial Fibrillation on CLL

03/24/2022

True or False: Patients with CLL with atrial fibrillation may be at a significantly decreased risk of all-cause mortality, cardiac-related mortality, and stroke.

True or False: Patients with CLL...

03/24/2022

Journal of Clinical Pathways

Quiz

Quiz: Cost-Effectiveness of Primary Prophylaxis With Biosimilar Filgrastim-sndz

03/23/2022

True or False: Primary prophylaxis with biosimilar filgrastim-sndz is cost-effective in patients at intermediate risk for febrile neutropenia receiving curative chemotherapy for breast cancer, NSCLC, and NHL.

True or False: Primary...

03/23/2022

Journal of Clinical Pathways

Quiz

Quiz: Trastuzumab Biosimilar for HER2-Positive Breast Cancer

03/17/2022

True or False: Trastuzumab biosimilars are safe and effective compared to the reference drug and improve patients' accessibility to breast cancer treatment.

True or False: Trastuzumab...

03/17/2022

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Quizzes

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products